A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of an Diclofenac 2% (w/w) cutaneous solution applied twice daily in patients with acute uncomplicated unilateral ankle sprain for a period of 7 consecutive days

Trial Profile

A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of an Diclofenac 2% (w/w) cutaneous solution applied twice daily in patients with acute uncomplicated unilateral ankle sprain for a period of 7 consecutive days

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Diclofenac (Primary)
  • Indications Musculoskeletal disorders; Repetitive strain injuries; Sports injuries; Sprains
  • Focus Registrational; Therapeutic Use
  • Sponsors Nuvo Research
  • Most Recent Events

    • 13 Jul 2016 According to Nuvo Pharmaceuticals media release, based upon the results of this study which shows the change in Pain on movement (POM) from day 1 to day 5 as non-significant but at day 3 as significant, company plans for a new phase III study in Germany with primary endpoint as change in Pain on movement (POM) from day 1 to day 3.
    • 10 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 07 Mar 2016 Results published in Nuvo Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top